Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

被引:2
|
作者
Becker, Andreas [1 ]
Krebs-Brown, Axel [1 ]
Vetter, Claudia [1 ]
Reuter, Tanja [1 ]
Rodriguez-Gutierrez, Almudena [2 ,3 ]
You, Xiaoli [4 ]
Lissy, Michael [5 ]
机构
[1] Healthcare Business Merck KGaA, Frankfurter Str 250,F135-003, D-64293 Darmstadt, Germany
[2] SLU, Merck, Madrid, Spain
[3] Merck KGaA, Darmstadt, Germany
[4] EMD Serono, Billerica, MA USA
[5] NUVISAN GmbH, Neu Ulm, Germany
来源
关键词
CRYO-EM STRUCTURE; PK; ATM;
D O I
10.1111/cts.13657
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peposertib is an orally administered inhibitor of DNA-dependent protein kinase. We evaluated the effect of food on its pharmacokinetics, and examined the pharmacokinetics of an oral suspension (OS) of disintegrated tablets, in a phase I, open-label, crossover three-period study (NCT04702698). Twelve healthy volunteers were randomized to one of six treatment sequences. They received a single dose of peposertib 100 mg as film-coated tablets under fasted or fed conditions ("tablet fasted" or "tablet fed") or as an OS under fasted conditions ("OS fasted"), with washout between treatments. Using healthy volunteers was possible because, despite its mechanism of action being suppression of DNA repair, peposertib has shown no genotoxic effect in animals. A mild food effect was observed with peposertib tablets. Fed-to-fasted ratios were: area under the curve from time 0 to time t (AUC(0-t)), 123.81% (90% confidence interval [CI]: 108.04, 141.87%); AUC from zero to infinity (AUC(0-infinity)), 110.28% (90% CI 100.71, 120.77%); and maximum concentration (C-max) 104.47% (90% CI: 79.15, 137.90%). C-max was delayed under fed conditions (median time to maximum concentration [T-max] was 3.5 h [tablet fed] vs. 1 h [tablet fasted]). OS-to-tablet (fasted) ratios were: AUC(0-t), 124.83% (90% CI: 111.50%, 139.76%); AUC(0-infinity), 119.05% (90% CI: 104.47, 135.67%); and C-max 173.29% (90% CI: 135.78, 221.16%). Median T-max was 0.5 h (OS fasted) versus 1 h (tablet). All treatments were well-tolerated in healthy volunteers. Peposertib tablets can be taken with or without food; if combined with chemotherapy or radiotherapy, the delay in C-max must be considered to optimize the chemo- or radiosensitizing effect. The peposertib OS form represents an alternative route of administration in patients with specific cancers causing dysphagia. However, the OS form should be part of future dose optimization strategies in relevant settings.
引用
收藏
页码:2628 / 2639
页数:12
相关论文
共 50 条
  • [21] Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
    Yan-ping Liu
    Ming-hui Hu
    Ping-ping Lin
    Ting Li
    Shu-qin Liu
    Yu-ya Wang
    Shao-rong Li
    Xiang-kun Li
    Chen-jing Wang
    Yu Cao
    Drugs in R&D, 2022, 22 : 175 - 182
  • [22] Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
    Liu, Yan-ping
    Hu, Ming-hui
    Lin, Ping-ping
    Li, Ting
    Liu, Shu-qin
    Wang, Yu-ya
    Li, Shao-rong
    Li, Xiang-kun
    Wang, Chen-jing
    Cao, Yu
    DRUGS IN R&D, 2022, 22 (02) : 175 - 182
  • [23] A Randomized, Phase I, 3-way Crossover Study to Examine the Effects of Food on the Pharmacokinetics of Single Doses of 400 mg Posaconazole Oral Suspension in Healthy Male Taiwanese Subjects
    Lin, Te-Yu
    Yang, Min-Hui
    Chang, Feng-Yee
    THERAPEUTIC DRUG MONITORING, 2013, 35 (02) : 223 - 227
  • [24] A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
    Trucksis, Michele
    Friedman, Evan
    Taylor, Adekemi
    Delgado, Liliana
    Reynders, Tom
    DeSmet, Marina
    Dong, Yingwen
    Fu, Irong
    DeMeyer, Igance
    Chodakewitz, Jeffrey
    Iwamoto, Marian
    Wagner, John
    CANCER RESEARCH, 2009, 69
  • [25] Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling
    Liu, Stephanie N. N.
    Agarwal, Priya
    Heinig, Katja
    Datye, Asim
    Sturm-Pellanda, Carolina
    Crugnola, Andrea
    Arca, Marc
    Miles, Dale
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (06): : 1085 - 1096
  • [26] Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects
    Linlin Hu
    Qiuyue Sun
    Lu Tang
    Mingmin Cai
    Wei Qian
    Ting Dou
    Huiping Wang
    Yong Wu
    Yongqiang Liu
    Clinical Drug Investigation, 2024, 44 : 79 - 85
  • [27] Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects
    Hu, Linlin
    Sun, Qiuyue
    Tang, Lu
    Cai, Mingmin
    Qian, Wei
    Dou, Ting
    Wang, Huiping
    Wu, Yong
    Liu, Yongqiang
    CLINICAL DRUG INVESTIGATION, 2024, 44 (01) : 79 - 85
  • [28] Pharmacokinetics of Lacosamide and Omeprazole Coadministration in Healthy Volunteers: Results from a Phase I, Randomized, Crossover Trial
    Willi Cawello
    Christa Mueller-Voessing
    Andreas Fichtner
    Clinical Drug Investigation, 2014, 34 : 317 - 325
  • [29] Pharmacokinetics of Lacosamide and Omeprazole Coadministration in Healthy Volunteers: Results from a Phase I, Randomized, Crossover Trial
    Cawello, Willi
    Mueller-Voessing, Christa
    Fichtner, Andreas
    CLINICAL DRUG INVESTIGATION, 2014, 34 (05) : 317 - 325
  • [30] PHASE I, RANDOMIZED, CROSSOVER STUDY TO COMPARE THE DAY VS. NIGHT PHARMACOKINETICS OF A SINGLE ORAL DOSE OF A NEW ZALEPLON FORMULATION IN HEALTHY YOUNG VOLUNTEERS
    Staner, L.
    Luthringer, R.
    Viardot, G.
    Metzger, D.
    Tisserant, A.
    Osbakken, M. D.
    McCormick, A.
    Walsh, J. K.
    Greenblatt, D. J.
    SLEEP, 2010, 33 : A221 - A221